Epidermal Growth Factor (EGF) for Wound Healing and Skin Rejuvenation — Skin & Hair
Recombinant human EGF activates the EGFR/ErbB1 tyrosine kinase signaling cascade to stimulate keratinocyte and fibroblast proliferation, accelerating wound healing and reducing signs of skin aging.
Overview
Epidermal Growth Factor (EGF) is a 53-amino acid polypeptide originally discovered by Stanley Cohen (Nobel Prize 1986) that binds to the EGF receptor (EGFR/ErbB1) on keratinocytes, fibroblasts, and endothelial cells. Upon receptor binding, EGF triggers a tyrosine kinase signaling cascade activating the RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways, stimulating cell proliferation, differentiation, and survival. Clinical studies in the Journal of Drugs in Dermatology and Dermatologic Surgery demonstrate that topical rhEGF (recombinant human EGF) at 1-10 ppm concentrations significantly accelerates wound healing in burns, chronic ulcers, and post-laser resurfacing recovery. For anti-aging applications, RCTs show improvements in wrinkle depth, skin thickness, and elasticity after 8-12 weeks of topical application. EGF levels decline with age, contributing to slower wound healing and reduced epidermal turnover. However, theoretical oncological concerns exist given EGFR's role in cancer cell proliferation, warranting caution in patients with history of EGFR-positive malignancies.
Indications
- Wound healing acceleration (burns, surgical wounds, chronic ulcers)
- Post-procedural skin recovery (laser resurfacing, microneedling, chemical peels)
- Fine lines and wrinkles (anti-aging)
- Skin thinning and fragility in aged skin
- Diabetic wound healing (FDA-approved: becaplermin/PDGF analog)
- Radiation dermatitis management
Mechanism of Action
EGF binds the extracellular domain of EGFR (ErbB1), inducing receptor homodimerization or heterodimerization with ErbB2/ErbB3, activating the intrinsic tyrosine kinase domain
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Recombinant Human EGF (rhEGF) | 1-10 ppm (0.0001-0.001%) | Twice daily to wound bed | Applied after wound cleansing; cover with appropriate dressing |
| Recombinant Human EGF | 1-5 ppm in serum base | Once daily (PM) | Apply to cleansed skin; follow with moisturizer; results at 8-12 weeks |
| EGF + HA Combination | 5 ppm EGF + 0.5% HA | Twice daily for 7-14 days post-procedure | Begin 24 hours after laser/microneedling; accelerates re-epithelialization |
Evidence Grade
GRADE B
Safety & Contraindications
- Theoretical concern regarding EGFR-driven cancer promotion; avoid in patients with active or history of EGFR-positive malignancies
- Topical concentrations (1-10 ppm) have not demonstrated systemic absorption in pharmacokinetic studies
- Not recommended on actively infected wounds without concurrent antimicrobial therapy
- Rare mild irritation or erythema at application site
- Long-term safety data (>2 years) limited for anti-aging topical use
- Ensure product uses recombinant human EGF (rhEGF) from validated sources for purity